Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease: attrition rate and evolution of disease activity

類似資料

• Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity
  著者:: Cruyssen, Bert Vander, 等
  出版事項: (2006)
• Response to the commentary 'Pooled indices to measure rheumatoid arthritis activity: a good reflection of the physician's mind'
  著者:: Vander Cruyssen, Bert, 等
  出版事項: (2006)
• The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry: clues for the optimization of rituximab treatment strategies
  著者:: Vander Cruyssen, Bert, 等
  出版事項: (2010)
• 74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis
  著者:: Delabaye, Isabelle, 等
  出版事項: (2010)
• DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment
  著者:: Vander Cruyssen, Bert, 等
  出版事項: (2005)